Climb Biotherapeutics, Inc.
CLYM
We are a clinical-stage biotechnology company committed to developing potential best-in-class therapeutics that address significant unmet need for patients living with immune-mediated diseases. We have built our pipeline by strategically acquiring or in-licensing product candidates that we believe have clear biological rationale, well-defined development pathways, and the poten…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$59M
▲ +19.0% YoY
Op. Margin
–
ROIC
-27.06%
▲ +11.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$53M
▼ -250.5% YoY
Op. Cash Flow (TTM)
-$53M
▼ -249.3% YoY
Net Debt
-$204M
Net Cash Position
Cash & Equiv.
$205M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with CLYM
Held by ETFs
CLYM is in 15 US ETFs. The largest of them, with CLYM's weight in each:
iShares Russell 2000 Growth ETFIWO0.01%of the fund
State Street SPDR S&P Biotech ETFXBI0.11%of the fund
Vanguard U.S. Momentum Factor ETFVFMO0.12%of the fund
Vanguard Russell 2000 Growth ETFVTWG0.01%of the fund
iShares Micro-Cap ETFIWC0.09%of the fund
Fidelity Fundamental Small-Mid Cap ETFFFSM0.11%of the fund
Climb Biotherapeutics (CLYM) in two numbers
Questions about Climb Biotherapeutics
Does Climb Biotherapeutics (CLYM) pay a dividend?
No. Climb Biotherapeutics (CLYM) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 30 Oct 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in CLYM's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CLYM
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.